Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:16:35 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Amniotics Q1 2023 - NK-program Initiated but under Financial Strain

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Amniotics Q1 2023 - NK-program Initiated but under Financial Strain

2023-05-05 13:53:00

Amniotics finished the clinical trial of Pulmostem in Q1 and is now analysing the data. The grant for the NK cell-based therapies project was paid to Amniotics as leader of the consortium. Amniotics also received some cash from the rights issue. However, the net cash position will not finance the company through the rest of the year.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/